NasdaqHealth CarePharmaceutical PreparationsHOUSTON, TX

CNS Pharmaceuticals, Inc. CNSP

Ask your AI

The reported share count looks too low next to the company’s average share countCIK 1729427

Insider trades, 12 mo

2 buys · 0 sells

$44.0K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

4.5% of shares · 1 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in CNS Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 12, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in CNS Pharmaceuticals, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

2 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since May 18, 2026. Insiders have two business days to file.

Recent insider trades

Michal Fisher Director	May 18 Form 4 ↗	Buy	+$10.0K 2,000 sh @ $5.00	-40.8%
Faith L. Charles Director	May 18 Form 4 ↗	Buy	+$34.0K 7,100 sh @ $4.79	-40.8%

All CNSP insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

66,094 shares

8 funds report CNSP. Values checked against market prices.

Funds own 19% of shares (Q2 2026)

11 funds hold the stock.

Q3 2026: 4.5% · 5,560 of ~8,900 funds reported so far

Q2 2025<0.1%
Q3 20254.0%
Q4 202520%
Q1 202618%
Q2 202619%
Q3 2026 (so far)4.5%

Q3 2026. 1 new, 1 added to, 3 trimmed, 4 exited since Q2 2026.

Top 13F holders
#
1	Stonepine Capital Management, LLC 13F ↗	39,942	$211.7K	-3.9%
2	Vanguard Capital Management LLC 13F ↗	15,760	$83.5K	+125.4%
3	Vanguard Fiduciary Trust Co 13F ↗	10,226	$54.2K	unchanged
4	UBS Group AG 13F ↗	130	$689	-91.1%
5	FMR LLC 13F ↗	26	$136	New
6	Barrett & Company, Inc. 13F ↗	8	$42	unchanged
7	Barclays plc 13F ↗	1	$5	-94.7%
8	Danske Bank A/S 13F ↗	1	$5	unchanged

Download CSV Every fund that holds CNSP, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What CNS Pharmaceuticals, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What CNS Pharmaceuticals, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q2 2025	1	—	1	$11
Q3 2025	8	+7	24,616	$221.5K
Q4 2025	9	+1	124,237	$652.2K
Q1 2026	11	+2	145,596	$348.7K
Q2 2026	11	0	280,434	$1.3M
Q3 2026	8	-3	66,094	$350.3K

Each point is a quarter-end, from Q2 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (18978H508). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-12 on Jul 22, 2025): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes4 in 12 mo 8-K events1 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcement1 release on record Clinical trials1 active IPO history8 registrations Merger clearancesLatest Jan 27 Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: CNS Pharmaceuticals, Inc.
Address: 2100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX 77027
Phone: 1-800-946-9185
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: NV
Listed as: CNSP (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$2.89−$0.73 (−20.17%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $2.89 · High $5.35Nov 13, 2026

Aug 13, 2026Low $2.89 · High $6.01Nov 13, 2026

Nov 13, 2025Low $2.13 · High $7.84Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.